Drugs / Recombinant Human Coagulation FVIII
Recombinant Human Coagulation FVIII
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT03947320 | Dec 2019 → Sep 2020 | hemophilia A | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04061109 | May 2019 → Mar 2020 | hemophilia A | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03815318 | Jan 2019 → Jan 2020 | hemophilia A | Sinocelltech Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03947567 | Jul 2019 → Apr 2025 | hemophilia A | Sinocelltech Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Coagulation FVIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03947320 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Coagulation FVIII” NCT03815318 ↗ |
| Route | Intravenous | “Subjects shall receive FVIII intravenous injection treatment” NCT03815318 ↗ |